Zobrazeno 1 - 10
of 1 333
pro vyhledávání: '"W-H Chow"'
Autor:
S. Karami, P. Brennan, M. Navratilova, D. Mates, D. Zaridze, V. Janout, H. Kollarova, V. Bencko, V. Matveev, N. Szesznia-Dabrowska, I. Holcatova, M. Yeager, S. Chanock, N. Rothman, P. Boffetta, W-H. Chow, L. E. Moore
Publikováno v:
International Journal of Endocrinology, Vol 2010 (2010)
Mediated by binding to the high-affinity vitamin D receptor (VDR), vitamin D forms a heterodimer complex with the retinoid-X-receptor (RXR). Variation in both genes has been shown to modify renal cell carcinoma (RCC) risk. Therefore, we investigated
Externí odkaz:
https://doaj.org/article/fc79733b8b234c8ea00ef698710145e3
Publikováno v:
Obesity Science & Practice. 2:309-317
SummaryObjective Obesity is a metabolic disease. However, the underlying molecular mechanisms linking metabolic profiles and weight gain are largely unknown. Methods Here, we used semi-targeted metabolomics to assay 156 metabolites selected from 25 k
Publikováno v:
Metallurgical and Materials Transactions A. 44:3532-3543
Molten Fe79.5B6.5C14 melts can be cast into ingots of networklike microstructure. According to microstructural classification, a Fe79.5B6.5C14 network specimen can be divided into three zones. Zone A is occupied by a random network, zone B by a unifo
Publikováno v:
Obesity Science & Practice
Summary Objective Obesity is a metabolic disease. However, the underlying molecular mechanisms linking metabolic profiles and weight gain are largely unknown. Methods Here, we used semi‐targeted metabolomics to assay 156 metabolites selected from 2
Autor:
Sharon A. Savage, Barry I. Graubard, Mark P. Purdue, M Hoxha, Kendra Schwartz, Julie J. Ruterbusch, Bridget J. McCarthy, Andrea A. Baccarelli, Jonathan N. Hofmann, Sholom Wacholder, Joanne S. Colt, Nathanial Rothman, W-H Chow, Faith G. Davis
Publikováno v:
British Journal of Cancer
BACKGROUND: There are few known risk factors for renal cell carcinoma (RCC). Two small hospital-based case–control studies suggested an association between short blood telomere length (TL) and increased RCC risk. METHODS: We conducted a large popul
Autor:
L. Gallicchio, L. E. Moore, V. L. Stevens, J. Ahn, D. Albanes, V. Hartmuller, V. W. Setiawan, K. J. Helzlsouer, G. Yang, Y.-B. Xiang, X.-O. Shu, K. Snyder, S. J. Weinstein, K. Yu, A. Zeleniuch-Jacquotte, W. Zheng, Q. Cai, D. S. Campbell, Y. Chen, W.-H. Chow, R. L. Horst, L. N. Kolonel, M. L. McCullough, M. P. Purdue, K. L. Koenig
Publikováno v:
American Journal of Epidemiology. 172:47-57
Although the kidney is a major organ for vitamin D metabolism, activity, and calcium-related homeostasis, little is known about whether this nutrient plays a role in the development or the inhibition of kidney cancer. To address this gap in knowledge
Autor:
Luo, Yu1,2 (AUTHOR), Guan, Bing1 (AUTHOR), Deng, Xiaoqi3 (AUTHOR), Bai, Peide1 (AUTHOR), Huang, Haichao1 (AUTHOR), Miao, Chaohao1 (AUTHOR), Sun, Anran1 (AUTHOR), Li, Zhipeng1 (AUTHOR), Yang, Dianqiang4 (AUTHOR), Wang, Xuegang1 (AUTHOR), Shao, Zhiqiang5 (AUTHOR), Wu, Yulong6 (AUTHOR), Xing, Jinchun1 (AUTHOR) jcxing@xmu.edu.cn, Chen, Bin1 (AUTHOR) binchen@xmu.edu.cn, Wang, Tao1 (AUTHOR) taowang@xmu.edu.cn
Publikováno v:
Advanced Science. 10/16/2024, Vol. 11 Issue 38, p1-17. 17p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
W. H. Chow, R. Suryawan, H. Q. Tri Ho, K. H. Mak, S. Piyamitr, Juey-Jen Hwang, S. Javier, R. Zambahari, O.-H. Kwok
Publikováno v:
International Journal of Clinical Practice. 61:473-481
Several therapeutic approaches have been developed to improve the outcome among patients with acute coronary syndrome (ACS). However, treatment with antithrombotic therapies such as oral glycoprotein IIb/IIIa inhibitors has been limited by the lack o
Autor:
X.-C. Sun, W.-H. Chow, C.-Y. Pan, X.-X. Zhu, G.-W. Li, C. Davies, H. Tian, W.-Y. Yang, J. Jiang, H.-L. Shi
Publikováno v:
Diabetes Technology & Therapeutics. 5:33-42
The effects of adding rosiglitazone to existing sulfonylurea (SU) treatment have not previously been studied in Chinese patients with type 2 diabetes and no known pre-existing hepatic impairment. Patients were randomized to receive rosiglitazone 2 mg